Evaluate the avidity of T cells engaged by bispecific antibodies

Part of: Bispecific Antibodies

Evaluate the avidity of T cells engaged by bispecific antibodies

Bispecific antibodies are power tools adopted by immuno-oncology that can enhance the recruitment of T cells to specific cancer cells. The z-Movi expands the set of parameters to select the best antibodies for optimal T cell responses.

In a collaborative study, we compared cell avidities between T cells and target cancer cells in the presence of bispecific antibodies (BsAb) or control conditions (no antibodies or non-specific antibodies).

T cells with BsAb required stronger pulling forces to detach from the tumor cells when compared with the two controls (Figure 1).

Future cell avidity analyses of engineered BsAb, will enable researchers to discover and fine-tune optimal antibodies for T cell therapies.

1 Left: Avidity curve representing the average proportion of bound T cells (BsAb-engaged or control conditions) upon an applied force ramp. Right: Bar graph representing percentage of target-bound T cells at the minimal force (based on no BsAb negative control-detachment) as gated from the avidity curve. (rForce indicates relative force).

Solutions

z-Movi® High-throughput Label-free Cell Interaction Studies
z-Movi®

Cell Avidity Analyzer

The z-Movi® is a unique instrument that measures the avidity between immune cells and their targets, enabling you to identify the most potent immunotherapeutic effector cells. This new technology provides you with predictive, reproducible, and fast high-throughput results at a single-cell resolution without compromising cell viability. All within a compact little box that easily fits inside the flow hood for sterile and safe sample handling

    Want to learn more?

    Would you like to receive exclusive news on the latest products, single-molecule events and breakthrough science from us?


    You can unsubscribe at any time from our marketing emails. By submitting the form you agree to LUMICKS' privacy policy.